Developing breakthrough oncology drug candidates

Strong partnerships are essential for research. Johan Emilsson, CEO of Sprint Biosciences, and Lionel Trésaugues, Director of Structure-Based Drug Design at Sprint Biosciences, were interviewed during a visit to MAX IV about the long-standing collaboration between the company and the research facility. MAX IV plays an important role in Swedish and international research by providing researchers and companies […]

Sprint Bioscience, in collaboration with MAX IV, has been awarded approximately 940,000 kronor in funding from Vinnova for a joint research project on alternative methods for fragment screening, with the aim of improving future drug development programs. The project combines Sprint Bioscience’s expertise in fragment-based drug discovery with MAX IV’s world-leading research infrastructure. ”The fact that Vinnova is awarding funding to this project together with MAX IV […]

The Flemingsberg Science Foundation is a neutral actor in the regional development of southern Stockholm, with a mission to promote and spearhead the development of knowledge-intensive activities in Flemingsberg. Part of Flemingsberg Science is the Life Science Cluster Flemingsberg, an ERDF project aimed at fostering growth in the life sciences. Read more about the initiative here. In Flemingsberg…

Sprint Bioscience summarizes below the company’s upcoming meetings with potential partners and investors during the second half of 2026. The list is subject to change and is available on the company’s website. International partnering conferences: September 8–9, 2026 Nordic Life Science Days, Stockholm, Sweden https://nlsdays.com/ September 14–16, 2026 IPLS, International Partnering in Life Science Society Annual Conference, Stockholm, Sweden, https://ipls.online/events/, October 7–9, 2026, Bio Japan, Yokohama, Japan, https://jcd-expo.jp/en/, November 9–11 […]